EOM Pharmaceutical Holdings Inc. (IMUC)

[bob smith]

Important Question that probably will not be clarified untill, twds the end of the phase 2 results.

Since we have limited - tacitile treatment plans, unlike what we are seeing from IMUC (though its only a single arm study). it can be priceless.

current treatment modalities including gamma knife and and yearly costs range from $25,000 to $100,000 / year for each patient.

for example: Bevacizumab costs range from $30,000 to $65,000 a year/patient in various platforms in united states and england (NHS).

This is truly speculative, but propriety benefits to IMUC, and licensing treatment plans to other oncologic disease pathways is priceless can quadruple the above numbers for the company.

Im sure the company will have conference call when this are all said and done twds the end of phase 2 trials.


time will tell.


gl